Why MedTech Is Buying Innovation While Pharma Is Borrowing It

MedTech companies are buying their way to innovation. Pharma and biotech are building networks to share the load. Both are responding to the same forces—rising R&D costs, regulatory complexity and pressure to move faster with less—but the strategies couldn't look more different. 

Understanding why these paths are diverging matters, whether you're a startup trying to get acquired, an R&D leader choosing where to invest, or a contract partner positioning for what comes next. 

Medical Device Innovation: The Acquisition Engine 

For medical device companies, acquisition has become the primary engine of innovation. In Q1 of 2025, MedTech M&A hit $9.2 billion—more than triple the $2.7 billion from the same period a year earlier. Facing relentless competition, tighter margins, and shorter product cycles, the big players aren't waiting for internal R&D to deliver. They're buying innovation ready-made (or at least already de-risked). 

The pattern is clear in recent deals:  

• Stryker's $4.9 billion acquisition of Inari Medical gives it immediate entry into the peripheral vascular market. 
• Medtronic's purchase of Fortimedix Surgical strengthens its surgical instrument portfolio.  
• Boston Scientific's acquisition of Bolt Medical expands its cardiovascular technology.  

In each case, the logic is the same: buy the technology, absorb the team, integrate fast. This model has created a self-reinforcing ecosystem. Startups build with an eye toward acquisition, while established players acquire to maintain momentum. Speed and integration are the competitive advantages. 

Pharma and Biotech Development: The Collaboration Network 

Pharmaceutical and biotech companies are playing a different game. Drug development costs roughly $2.2 billion per approved therapy and takes more than a decade. The science is uncertain. The regulatory path is long. Acquiring early-stage biotech companies is riskier when you can't know for years whether the asset will pan out. 

So instead of consolidating, pharma is distributing. Companies are expanding their reliance on contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and academic partners to share cost, capacity and risk. In 2024, licensing and partnership deal values reached approximately $183 billion, with 28 agreements exceeding $100 million in upfront payments. 

The rationale is structural. Drug pipelines are increasingly specialized (targeted biologics, rare diseases, personalized therapies), requiring niche expertise no single company can maintain. Long-term alliances with CROs and CDMOs let pharma tap global talent and advanced platforms while controlling fixed costs. Collaboration, not consolidation, has become the engine of progress. 

What This Means for R&D Partners 

These diverging models are reshaping what contract research and development partners need to offer—and when they need to show up. 

Across both industries, outsourcing is no longer about overflow capacity. It’s about bringing in collaborators who can extend core competencies, provide scientific and technical depth and keep programs on track despite uncertainty. Whether your path is acquisition-driven or network-driven, several traits consistently distinguish true innovation partners from transactional vendors: 

• Scientific and technical depth: Multidisciplinary expertise and fluency in both the science and the development processes. 
• Curiosity and context: Partners who understand the problem, not just the scope. 
• Process discipline with flexibility: Structured project management that can adapt as new information emerges. 
• Shared accountability: Alignment around outcomes, risk and success metrics—not just deliverables. 

The right time to engage an external partner is when the complexity of your program exceeds your internal capacity or specialization. In MedTech, that moment often arrives around verification, validation and integration. In biopharma, it often arrives earlier, when proof-of-concept studies, regulatory strategy or specialized manufacturing become limiting factors. 

The most successful organizations in both sectors are those that bring in partners early enough to avoid costly pivots later in development. 

Battelle works across the full healthcare innovation spectrum, supporting both MedTech and biopharma teams as their development strategies evolve. We see firsthand how acquisition-driven and network-driven models are reshaping expectations for external partners—and how the right support at the right moment can de-risk development, accelerate progress and strengthen the path to market. 

Whether the goal is early design support, complex testing, regulatory alignment or preparing a technology for acquisition or scale, our teams bring the technical depth, systems thinking and scientific rigor needed to move innovations forward. 

Contact our experts for guidance on navigating today’s evolving R&D landscape and de-risking your next development milestone.